Stem cells therapy for treatment of diabetic mellitus and complications

doi:10.3969/j.issn.2095-4344.2012.49.028

Abstract

Abstract:

BACKGROUND: Type 2 diabetes mellitus can be effectively treated by drugs, but it still continues to progress. Recently, stem cells in particular mesenchymal stem cells for treatment of type 2 diabetes mellitus have been paid increasing attention, and a series of basic and clinical studies have been made.
OBJECTIVE: To summarize and analyze the research progress in stem cells therapy for treatment of type 2 diabetes mellitus and complications, which provide direction for future clinical studies.
METHODS: A computer-based online retrieval was performed by the first author in PubMed database for searching the papers describing stem cells therapy for treatment of type 2 diabetes mellitus and the complications published between January 1981 and January 2012 in English with the key word “diabetic mellitus, stem cells, mesenchymal stem cells, complication, therapy”. Repetitive studies were excluded and 57 papers were included in the final analysis.
RESULTS AND CONCLUSION: Stem cells can be used to treat type 2 diabetes mellitus by promoting pancreatic β-cell survival and regeneration and reducing apoptosis. Furthermore, stem cells can also be used to treat the complications of type 2 diabetes mellitus including diabetic cardiomyopathy and neuropathy. Adult stem cells, in particular mesenchymal stem cells, are more suitable for use as seed cells because of convenient harvest, low immunogenicity and no ethical disputes, and become the focus for current and future studies regarding treatment of type 2 diabetes mellitus and complications.

CLC Number:

R318

Wang Yan-gang, Yu Jiang-su. Stem cells therapy for treatment of diabetic mellitus and complications

[J]. Chinese Journal of Tissue Engineering Research, 2012, 16(49): 9276-9282.

Figures/Tables 1

References

[1] Li L, Li F, Qi H, et al. Coexpression of Pdx1 and beta cell insulin in mesenchymal stem cells could promote the differentiation of nestin-positive epithelium-like progenitors and pancreatic islet-like spheroids. Stem Cells Dev. 2008; 17(4):815-823.

[2] Chang CF, Hsu KH, Chiou SH, et al. Fibronectin and pellet suspension culture promote differentiation of human mesenchymal stem cells into insulin producing cells. J Biomed Mater Res A. 2008;86(4):1097-1105.

[3] Ciceri F, Piemonti L. Bone marrow and pancreatic islets: an old story with new perspectives. Cell Transplant. 2010; 19(12): 1511-1522.

[4] Simard AR, Soulet D, Gowing G, et al. Bone marrow-derived microglia play a critical role in restricting senile plaque formation in Alzheimer's disease. Neuron. 2006;49(4):489- 502.

[5] Lee JK, Jin HK, Endo S, et al. Intracerebral transplantation of bone marrow-derived mesenchymal stem cells reduces amyloid-beta deposition and rescues memory deficits in Alzheimer's disease mice by modulation of immune responses. Stem Cells. 2010;28(2):329-343.

[6] Valle-Prieto A, Conget PA. Conget. Human mesenchymal stem cells efficiently manage oxidative stress. Stem Cells Dev. 2010;19(12):1885-1893.

[7] Waterman RS, Betancourt AM. Treating Chronic Pain with Mesenchymal Stem Cells: A Therapeutic Approach Worthy of Continued Investigation. J Stem Cell Res Ther. 2011 S2:001. doi:10.4172/2157-7633.

[8] Iyer SS, Rojas M. Anti-inflammatory effects of mesenchymal stem cells: novel concept for future therapies. Expert Opin Biol Ther. 2008;8(5):569-581.

[9] Ho JH, Tseng TC, Ma WH, et al. Multiple intravenous ransplantations of mesenchymal stem cells effectively restore long-term blood glucose homeostasis by hepatic engraftment and beta cell differentiation in streptozocin-induced diabetic mice. Cell Transplant. 2012;21(5):997-1009.

[10] Evans MJ, Kaufman MH. Establishment in culture of pluripotential cells from mouse embryos. Nature. 1981; 292: 154-156.

[11] Thomson JA, Itskovitz-Eldor J, Shapiro SS, et al. Embryonic stem cell lines derived from human blastocysts. Science. 1998; 282: 1145-1147.

[12] Assady S, Maor G, Amit M, et al. Insulin production by human embryonic stem cells. Diabetes. 2001;50:1691-1697.

[13] Soria B, Roche E, Berná G, et al. Insulin-secreting cells derived from embryonic stem cells normalize glycemia in streptozotocin-induced diabetic mice. Diabetes. 2000;49(2): 157-162.

[14] D'Amour KA, Bang AG, El iazer S, et al. Production of pancreatic hormone-expressing endocrine cells from human embryonic stem cells. Nat Biotechnol. 2006; 24: 1392-1401.

[15] Kroon E, Martinson LA, Kadoya K, et al. Pancreatic endoderm derived from human embryonic stem cells generates glucose-responsive insulin-secreting cells in vivo. Nat Biotechnol. 2008; 26: 443-452.

[16] Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fbroblast cultures by defned factors. Cell. 2006;126: 663-676.

[17] Takahashi K, Tanabe K, Ohnuki M, et al. Induction of pluripotent stem cells from adult human fbroblasts by defned factors. Cell. 2007; 131: 861-872.

[18] Yu J, Vodyanik MA, Smuga-Otto K, et al. Induced pluripotent stem cell lines derived from human somatic cells. Science. 2007;318:1917-1920.

[19] Alipio Z, Liao W, Roemer EJ, et al. Reversal of hyperglycemia in diabetic mouse models using induced-pluripotent stem (iPS)-derived pancreatic beta-like cells. Proc Natl Acad Sci U S A. 2010;107:13426-13431.

[20] Zhang D, Jiang W, Liu M, et al. Highly effcient differentiation of human ES cells and iPS cells into mature pancreatic insulin-producing cells. Cell Res. 2009; 19: 429-438.

[21] Herzog EL, Chai L, Krause DS. Plasticity of marrow-derived stem cells. Blood. 2003; 102: 3483-3493.

[22] Ianus A, Holz GG, Theise ND, et al. In vivo derivation of glucose-competent pancreatic endocrine cells from bone marrow without evidence of cell fusion. J Clin Invest. 2003; 111:843-850.

[23] Zhao M, Amiel SA, Ajami S, et al. Amelioration of streptozotocin-induced diabetes in mice with cells derived from human marrow stromal cells. PLoS One. 2008;3:e2666.

[24] Sun Y, Chen L, Hou XG, et al. Differentiation of bone marrow-derived mesenchymal stem cells from diabetic patients into insulin-producing cells in vitro. Chin Med J (Engl). 2007;120(9):771-776.

[25] Xie QP, Huang H, Xu B, et al. Human bone marrow mesenchymal stem cells differentiate into insulin-producing cells upon microenvironmental manipulation in vitro. Differentiation. 2009;77(5):483-491.

[26] Bhansali A, Upreti V, Khandelwal N, et al. Efficacy of autologous bone marrow-derived stem cell transplantation in patients with type 2 diabetes mellitus.Stem Cells Dev. 2009; 18: 1407-1416.

[27] Estrada EJ, Valacchi F, Nicora E, et al. Combined treatment of intrapancreatic autologous bone marrow stem cells and hyperbaric oxygen in type 2 diabetes mellitus. Cell Transplant. 2008; 17:1295-1304.

[28] Gao F, Wu DQ, Hu YH, et al. In vitro cultivation of islet like cell clusters from human umbilical cord blood-derived mesenchymal stem cells. Transl Res. 2008;151(6):293-302.

[29] Prabakar KR, Domínguez-Bendala J, Molano RD, et al. Generation of glucose-responsive, insulin-producing cells from human umbilical cord blood-derived mesenchymal stem cells. Cell Transplant. 2012;21(6);1321-1339.

[30] Kadam SS, Bhonde RR. Islet neogenesis from the constitutively nestin expressing human umbilical cord matrix derived mesenchymal stem cells. Islets. 2010;2(2):112-120.

[31] Parekh VS, Joglekar MV, Hardikar AA. Differentiation of human umbilical cord blood-derived mononuclear cells to endocrine pancreatic lineage. Differentiation. 2009;78(4): 232-240.

[32] Suen PM, Leung PS. Pancreatic stem cells: a glimmer of hope for diabetes? JOP. 2005; 6(5):422-424.

[33] Noguchi H, Matsumoto S, Ueda M, et al. Method for isolation of mouse pancreatic stem cells. Transplant Proc. 2008;40(2): 422-423.

[34] Zou C, Suen PM, Zhang Y, et al. Isolation and in vitro characterization of pancreatic progenitor cells from the islets of diabetic monkey models. Int J Biochem Cell Biol. 2006;38: 973-984.

[35] Bonner-Weir S, Taneja M, Weir GC, et al. In vitro cultivation of human islets from expanded ductal tissue. Proc Natl Acad Sci U S A. 2000; 97: 7999-8004.

[36] Gao R, Ustinov J, Pulkkinen MA, et al. Characterization of endocrine progenitor cells and critical factors for their differentiation in human adult pancreatic cell culture. Diabetes. 2003; 52: 2007-2015.

[37] Pittenger MF, Mackay AM, Beck SC, et al. Multilineage potential of adult human mesenchymal stem cells. Science. 1999;284:143-147.

[38] Poornima IG, Parikh P, Shannon RP. Diabetic cardiomyopathy: The search for a unifying hypothesis. Circ Res. 2006;98:596-605.

[39] Yoon YS, Uchida S, Masuo O, et al. Progressive attenuation of myocardial vascular endothelial growth factor expression is a seminalevent in diabetic cardiomyopathy: Restoration of microvascular homeostasis and recovery of cardiac function in diabetic cardiomyopathy after replenishment of local vascular endothelial growth factor. Circulation. 2005;111: 2073-2085.

[40] Jesmin S, Sakuma I, Hattori Y, et al. Role of angiotensin II in altered expression of molecules responsible for coronary matrix remodeling in insulin-resistant diabetic rats. Arterioscler Thromb Vasc Biol. 2003;23:2021-2026.

[41] Camp TM, Tyagi SC, Senior RM, et al. Gelatinase B (MMP-9) an apoptotic factor in diabetic transgenic mice. Diabetologia. 2003;46:1438-1445.

[42] Zhang N, Li J, Luo R, et al. Bone marrow mesenchymal stem cells induce angiogenesis and attenuate the remodeling of diabetic cardiomyopathy. Exp Clin Endocrinol Diabetes. 2008; 116:104-111.

[43] Wang X, Zhao T, Huang W, et al. Hsp20-engineered mesenchymal stem cells are resistant to oxidative stress via enhanced activation of Akt and increased secretion of growth factors. Stem Cells. 2009;27:3021-3031.

[44] Hare JM , Traverse JH,Henry TD, et al. A randomized, double-blind,placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction. J Am Coll Cardiol. 2009;54: 2277-2286.

[45] Lee JS, Hong JM, Moon GJ, et al. A long-term follow-up study of intravenous autologous mesenchymal stem cell transplantation in patients with ischemic stroke. Stem Cells. 2010;28:1099-1106.

[46] Amin AH, Abd Elmageed ZY, Nair D, et al. Modi?ed multipotent stromal cells with epidermal growth factor restore vasculogenesis and blood ?ow in ischemic hind-limb of type II diabetic mice. Lab Invest. 2010;90:985-996.

[47] Comerota AJ, Link A, Douville J, et al. Upper extremity ischemia treated with tissue repair cells from adult bone marrow. J Vasc Surg. 2010;52:723-739.

[48] Fazan R Jr, Dias da Silva VJ, Ballejo G, et al. Power spectra of arterial pressure and heart rate in streptozotocin-induced diabetes in rats. J Hypertens. 1999;17:489-495.

[49] Ezquer FE, Ezquer ME, Parrau DB, et al. Systemic administration of multipotent mesenchymal stromal cells reverts hyperglycemia and prevents nephropathy in type 1 diabetic mice. Biol Blood Marrow Transplant. 2008;14: 631-640.

[50] Lee RH, Seo MJ, Reger RL, et al. Multipotent stromal cells from human marrow home to and promote repair of pancreatic islets and renal glomeruli in diabetic NOD/scid mice. Proc Natl Acad Sci USA. 2006;103:17438-17443.

[51] Vinik AI, Park TS, Stansberry KB, et al. Diabetic neuropathies. Diabetologia. 2000;43:957-973.

[52] Shibata T, Naruse K, Kamiya H, et al. Transplantation of bone marrow-derived mesenchymal stem cells improves diabetic polyneuropathy in rats. Diabetes. 2008;57:3099-3107.

[53] Medina A, Scott PG, Ghahary A, et al. Pathophysiology of chronic nonhealing wounds. J Burn Care Rehabil. 2005;26: 306-319.

[54] Spanheimer RG. Correlation between decreased collagen production in diabetic animals and in cells exposed to diabetic serum: Response to insulin. Matrix. 1992;12:101-107.

[55] Kwon DS, Gao X, Liu YB, et al. Treatment with bone marrow-derived stromal cells accelerates wound healing in diabetic rats. Int Wound J. 2008;5:453-463.

[56] Wu Y, Chen L, Scott PG, et al. Mesenchymal stem cells enhance wound healing through differentiation and angiogenesis. Stem Cells. 2007;25:2648-2659.

[57] Le Blanc K, Pittenger M. Mesenchymal stem cells: Progress toward promise. Cytotherapy. 2005;7:36-45.